Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicadrostat plus empagliflozin initiation strategy study in chronic kidney disease
NL-OMON60630Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vicadrostat and empagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Absolute change in eGFR from baseline to Week 14 and Absolute change in eGFR from baseline to Week 16. Started Sep 2025; status: completed.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON60630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60630.